ClinicalTrials.gg
CompletedNCT01056874Updated Apr 7, 2011

Effect Of Maraviroc On The Pharmacokinetics Of Digoxin

A Phase 1 interventional study of Digoxin and Digoxin in Healthy and HIV Infections, sponsored by ViiV Healthcare. Completed at 1 site in Singapore. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-04-07.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
21 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing maraviroc in HIV Infections — none open to participants now, none under way, none of them phase 3. Maraviroc · HIV Infections.

Enrollment
38th of 44
12 · median 36
Started
2010
with 7 others
Phase 1
7 of 44
none open now
Registered
29th of 44
by date
Lead sponsor
8 of 44
ViiV Healthcare

Among the 44 studies testing maraviroc in HIV Infections, this one is the 38th largest by enrollment, is one of 8 that started in 2010, is one of 7 in phase 1, and was the 29th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 44 studies testing maraviroc in HIV Infections is open now. The open studies under HIV Infections, anywhere →

About maraviroc

Maraviroc: first FDA approval 2007 (SELZENTRY), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 21 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies testing maraviroc in HIV Infections as a file.
02

Study summary

This is an open labelled study to estimate the effect of maraviroc on the pharmacokinetics of digoxin, a probe for p-glycoprotein.

03

Conditions studied

  • Healthy
  • HIV Infections

Browse trials for

Keywords

  • Maraviroc
  • Digoxin
  • P-glycoprotein
  • Pharmacokinetics
  • Drug Interaction
  • HIV
04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and/or female subjects between the ages of 21 and 55 years, inclusive.
  • (BMI) of 17.5 to 25.5 kg/m2.
  • Total body weight >50 kg (110 lbs).

Exclusion criteria

Exclusion Criteria:

  • Treatment with an drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication.
  • Subjects with an estimated (CLcr) \<80 ml/min.
  • Pregnant or nursing females.
  • Females of who are unwilling or unable to use an acceptable method of as outlined in this protocol from at least 14 days prior to the first dose of study medication until completion of study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Active comparator
    Digoxin

    Drug: Digoxin

  • Experimental
    Digoxin + Maraviroc

    Drug: Digoxin · Drug: Maraviroc

Interventions

  • DrugDigoxin

    Oral Digoxin 0.25 mg single dose

  • DrugDigoxin

    Oral Digoxin 0.25 mg single dose on Day 5

  • Oral Maraviroc 300 mg twice daily for 6 days

    Also known as: Selzentry, Celsentri

06

What researchers measure

Primary outcomes

  1. To estimate the effect of multiple dose maraviroc on the pharmacokinetics of digoxin.

    Time frame: 21 days

Secondary outcomes

  1. To investigate the safety and tolerability of maraviroc and digoxin when co-administered.

    Time frame: 21 days

07

Study locations

1 site
  • Pfizer Investigational Site
    Singapore, 188770, Singapore
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2010
First posted
Jan 26, 2010
Start
Mar 2010
Primary completionActual
Apr 2010
CompletionActual
Apr 2010
Last update
Apr 7, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01056874
Lead sponsor
ViiV Healthcare
Collaborators
Pfizer
First posted
Jan 26, 2010
Start date
Mar 2010
Primary completion
Apr 2010
Completion
Apr 2010
Last update
Apr 7, 2011

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maraviroc

Start the discussion